Kurse werden geladen...
Prognose
| Kaufen | 2 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.» Mehr auf newsfilecorp.com
Best Value Stocks to Buy for May 28th
PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.» Mehr auf zacks.com
New Strong Buy Stocks for May 28th
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.» Mehr auf zacks.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −1,64 Mio | 18,07% |
| EBITDA | 0,00 | 100,00% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 9,00 Mio€ |
Anzahl Aktien | 4,80 Mio |
52 Wochen-Hoch/Tief | 8,42€ - 0,83€ |
| Dividenden | Nein |
Beta | 0,85 |
KGV (PE Ratio) | −13,88 |
KGWV (PEG Ratio) | −0,35 |
KBV (PB Ratio) | 7,72 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
| Name | Phio Pharmaceuticals Corp |
| CEO | Robert J. Bitterman |
| Mitarbeiter | 5 |
Assets entdecken
Shareholder von Phio Pharmaceuticals Corp investieren auch in folgende Assets
